For more than 20 years, I've dedicated my career at UCLA to combating digestive diseases like IBD, C. difficile, and obesity. My research leverages cutting-edge multiomics analysis, high-throughput drug screening, and machine learning to identify key biomarkers and therapeutic targets – proteins, miRNAs, and chemicals. This has led to the development of new treatments and a deeper understanding of these diseases. Supported by NIH grants and industry collaborations with companies like Merck, my lab has published many manuscripts and secured multiple US patents, contributing to FDA-approved therapies. We're equipped with state-of-the-art facilities, and I'm passionate about mentoring future scientists. My interdisciplinary approach allows me to translate findings across diseases, driving impactful research and ultimately improving patient outcomes.
For more than 20 years, I've dedicated my career at UCLA to combating digestive diseases like IBD, C. difficile, and obesity. My research leverages cutting-edge multiomics analysis, high-throughput drug screening, and machine learning to identify key biomarkers and therapeutic targets – proteins, miRNAs, and chemicals. This has led to the development of new treatments and a deeper understanding of these diseases. Supported by NIH grants and industry collaborations with companies like Merck, my lab has published many manuscripts and secured multiple US patents, contributing to FDA-approved therapies. We're equipped with state-of-the-art facilities, and I'm passionate about mentoring future scientists. My interdisciplinary approach allows me to translate findings across diseases, driving impactful research and ultimately improving patient outcomes.